Avenue Therapeutics, Inc. income statement ATXI

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Avenue Therapeutics, Inc. reported revenue of $1.4 million. It recorded a net loss of $2.9 million. The operating loss came to $3.1 million, an operating margin of -219.6%. Over the twelve months ended Jun 30, 2026, revenue was $0 and the net loss was $2.8 million.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017
Revenue	0	1	—	—	—	—	—	—
Research and development	1 -74.8%	1 -84.4%	3 +115.2%	1 -56.2%	3 -87.1%	22 +25.4%	18 +164.2%	7
Selling, general and administrative	2 -48.0%	4 -21.2%	5 +115.2%	2 +5.8%	2 -23.6%	3 -25.5%	4 +13.8%	4
Operating income	-3 +54.4%	-3 +72.7%	-8 -115.2%	-4 +28.3%	-5 +80.2%	-26 -20.4%	-22 -91.0%	-11
Income tax	—	0	—	—	—	—	—	—
Net income	-3	-3	-4 +4.8%	-4 +27.6%	-5 +80.1%	-26 -20.2%	-22 -75.8%	-12
Basic EPS	-0.86 -177.1%	-0.93 +94.1%	—	-0.22	—	—	—	—
Diluted EPS	—	—	—	-0.22	—	—	—	—
Weighted average shares, basic	3 +34.8%	3 +141.7%	2 +92.8%	1	—	—	—	—
Weighted average shares, diluted	—	—	2 +92.8%	1	—	—	—	—
Other measures
Interest coverage	—	—	—	—	—	—	—	-38.85x
Margins
Operating margin	—	-219.59%	—	—	—	—	—	—
Profit margin	—	-207.19%	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ATXI (OTC)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Bay Harbor Islands, FL
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1644963

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.